StreetInsider.com News Articles

Edwards Lifesciences faces stock risk ahead of trial results says Stifel

Thu, 22 Oct 2026 11:01:10 -0400

Investing.com -- Edwards Lifesciences may face more downside than upside risk heading into the TCT 2026 medical meeting, according to physician feedback gathered by Stifel ahead of the November 2 PROGRESS trial data release.

The PROGRESS trial examines whether transcatheter aortic valve replacement proves beneficial for patients with moderate aortic stenosis. Stifel spoke with four senior interventional cardiologists who expect the trial to meet its composite primary endpoint, which measures death or heart-failure events at two years.

The physicians indicated the trial will likely achieve its endpoint through the heart-failure component rather than mortality benefits. The doctors noted that two years of

Edwards Lifesciences faces stock risk ahead of trial results says Stifel

Thu, 22 Oct 2026 11:01:10 -0400

The physicians indicated the trial will likely achieve its endpoint through the heart-failure component rather than mortality benefits. The doctors noted that two years of

Belo Sun Receives Decision on Temporary Suspension of License Until Result of Settlement Hearing

Wed, 21 Oct 2026 08:13:00 -0400

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) announces that the Brazilian Supreme Court (“STF”) issued a decision on the request for suspension of provisional relief (Suspensão de Tutela Provisória) filed by Brazil’s Federal Public Prosecutor’s Office (“MPF”) concerning the Installation License (“LI”) for the Company’s Volta Grande Gold Project (the “Project”) in Pará, Brazil. The STF partially granted the MPF’s request, temporarily suspending the court ruling that had reinstated the effectiveness of the Project’s LI.

Clovis Torres, Chief Executive Officer of Belo

Belo Sun Receives Decision on Temporary Suspension of License Until Result of Settlement Hearing

Wed, 21 Oct 2026 08:13:00 -0400

Clovis Torres, Chief Executive Officer of Belo

Belo Sun Receives Decision on Temporary Suspension of License Until Result of Settlement Hearing

Wed, 21 Oct 2026 08:13:00 -0400

Clovis Torres, Chief Executive Officer of Belo

Belo Sun Receives Decision on Temporary Suspension of License Until Result of Settlement Hearing

Wed, 21 Oct 2026 08:13:00 -0400

Clovis Torres, Chief Executive Officer of Belo

Axonex AI implements 2-for-5 reverse stock split on Nasdaq

Tue, 20 Oct 2026 11:44:06 -0400

Axonex AI Group Limited (NASDAQ: AXNX), a Hong Kong-based company focused on artificial intelligence, robotics, and interior design services, is implementing a 2-for-5 reverse stock split of all its issued and unissued shares, effective at the opening of trading on October 22, 2026.

The reverse stock split, approved by the company's board of directors on October 2, 2026, will reduce the number of outstanding Class A ordinary shares from 15,190,742 to approximately 6,076,297. Every five shares will be consolidated into two shares. Fractional shares resulting from the split will be rounded up to the next whole number rather than issued as

Axonex AI implements 2-for-5 reverse stock split on Nasdaq

Tue, 20 Oct 2026 11:44:06 -0400

Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split

Tue, 20 Oct 2026 11:43:00 -0400

Hong Kong, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Axonex AI Group Limited (“Axonex” or the “Company”, NASDAQ: AXNX), a Hong Kong-based company with a strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, announces that it is implementing a reverse stock split of all of the Company’s issued and unissued shares, including the Class A ordinary shares with no par value (the “Class A Ordinary Shares”) and Class B ordinary shares with no par value (the “Class B Ordinary Shares,” together with the Class A Ordinary Shares,

Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split

Tue, 20 Oct 2026 11:43:00 -0400

Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split

Tue, 20 Oct 2026 11:43:00 -0400

Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split

Tue, 20 Oct 2026 11:43:00 -0400

TD Cowen on Boston Scientific (BSX): 'Cyberattack To Weigh on Q3 Results; We Remain Bullish on the Setup for 2027'

Tue, 20 Oct 2026 09:14:07 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $56.00 price target on Boston Scientific (NYSE: BSX).

The analyst commented: "Cyberattack To Weigh on Q3 Results; We Remain Bullish on the Setup for 2027; We view the recent cyberattack as a one-time event that likely has no negative impact beyond Q3. Because Street models have not been uniformly updated since the attack, Q3 and 2026 estimates remain artificially high. We think most investors get this and will look past a Q3 "miss" to the implied Q4 guide and any color on 2027. We are bullish on the 2027 outlook, especially

Boston Scientific (BSX) PT Lowered to $50 at Baird

Thu, 15 Oct 2026 07:21:59 -0400

Baird analyst David Rescott lowered the price target on Boston Scientific (NYSE: BSX) to $50.00 (from $53.00) while maintaining a Outperform rating.

Piper Sandler on Medtronic, Inc. (MDT): 'Positive Read-Through for MDT'

Wed, 14 Oct 2026 08:28:07 -0400

Piper Sandler analyst Matt O\'Brien reiterated a Neutral rating and $85.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst commented: "We surveyed 25 urologists and urogynecologists to assess trends across urology procedures through 2028. Results were most positive for MDT, with physicians expecting InterStim share gains and rapid Altaviva adoption. After conservatively hair cutting survey expectations, we estimate the two franchises could contribute 20-30 bps annually to MDT's top-line growth. For BSX, feedback was more mixed, with physicians expecting Axonics to remain a share donor and continued pressure across kidney stone devices. However, Bulkamid provides a notable offset and upcoming

Piper Sandler on Medtronic, Inc. (MDT): 'Positive Read-Through for MDT'

Wed, 14 Oct 2026 08:28:07 -0400

Piper Sandler analyst Matt O\'Brien reiterated a Neutral rating and $85.00 price target on Medtronic, Inc. (NYSE: MDT).

Boston Scientific (BSX) PT Lowered to $51 at Truist Securities

Wed, 14 Oct 2026 06:59:53 -0400

Truist Securities analyst Richard Newitter lowered the price target on Boston Scientific (NYSE: BSX) to $51.00 (from $57.00) while maintaining a Buy rating.

U.S. MedTech stocks: Q3 earnings preview